Идёт набор NCT06283966

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

Фаза III С лечением COPD (Chronic Obstructive Pulmonary Disease)

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: В протоколе указаны: BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg.
Кому может быть актуально: Состояния в реестре: COPD (Chronic Obstructive Pulmonary Disease). Базовые параметры: 40 лет — 80 лет · Все.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: США, Аргентина, Австралия, Австрия, Бразилия +32
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

A Randomized, Double-blind, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS)

Обзор

This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.

Подробное описание

This is a Phase III randomized, double-blind, parallel group, multi-center event-driven study comparing BGF MDI 320/14.4/9.6 μg BID with GFF MDI 14.4/9.6 μg BID in participants with COPD who are at risk of a cardiopulmonary event.

Вмешательства

Препарат BGF MDI 320/14.4/9.6 μg
Budesonide, glycopyrronium, and formoterol fumarate pressurized inhalation suspension
Препарат GFF MDI 14.4/9.6 μg
Glycopyrronium and formoterol fumarate pressurized inhalation suspension

Первичные конечные точки

Time to first severe cardiac or COPD event [Срок оценки: Up to 3 years]

Вторичные конечные точки (6)

Time to first severe COPD exacerbation event [Срок оценки: Up to 3 years]
Time to first severe cardiac event [Срок оценки: Up to 3 years]
Time to cardiopulmonary death [Срок оценки: Up to 3 years]
Moderate/severe COPD exacerbation rate [Срок оценки: Over time, up 3 years]
Time to Myocardial Infarction (MI) hospitalization or cardiac death [Срок оценки: Up to 3 years]
Time to Heart Failure (HF) acute healthcare visit/hospitalization or cardiac death [Срок оценки: Up to 3 years]

Критерии участия

Критерии включения

Male or female participants must be 40 to 80 years of age inclusive, at the time of signing

the ICF.

Demonstrate acceptable MDI administration technique at Visit 1 (V1) and Visit 2 (V2)
A diagnosis of COPD confirmed by a post-bronchodilator FEV1/FVC ratio < 70%

at V1.

Current or former smokers with a history of at least 10 pack-years of cigarette smoking;

defined as (number of cigarettes per day/20) x number of years smoked. Previous smokers are defined as those who have stopped smoking for at least 6

months prior to V1.

A baseline peripheral blood eosinophil count of ≥ 100 cells/mm3 assessed at Visit 1 by

the central laboratory

A CAT score of ≥ 10 at Visit 1.
Participant must fulfill at least 1 of the 4 CV disease/risk factor criteria below \[(a), (b),

(c), or (d)\]:

: Established CV Disease
: Combination of CV risk factors:

Hypertension
Diabetes Mellitus
Chronic Kidney Disease
Dyslipidemia
Obesity
: High risk of CV disease determined using an established CV risk assessment

tool.

: CT coronary Artery Calcification
Willing and, in the opinion of the investigator, able to adjust current COPD therapy, as

required by the protocol.

Willing to visit at the study site or participate in virtual visits as required per the protocol

to complete all study assessments.

A female is eligible to enter and participate in the study if the female is of:

Non-childbearing potential: either permanently sterilized or who are post-menopausal.
Childbearing potential: has a negative serum pregnancy test at V1 and must use one

highly effective form of birth control.

Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in the protocol.

Критерии исключения

Active diagnosis of asthma within the past 5 years (previous diagnosis as a child or adolescent are eligible), asthma-COPD overlap, or any other chronic respiratory disease other than COPD such as alpha-1 antitrypsin deficiency, active tuberculosis, lung fibrosis, sarcoidosis, interstitial lung disease, and pulmonary hypertension.
End-stage renal disease requiring renal replacement therapy
History of heart or lung transplant or actively listed for heart or lung transplant.
Implanted left ventricular assist device or implant anticipated in < 3 months.
History of lung cancer and/or treatment for lung cancer within the 5 years prior to Visit 1.
Unstable or life-threatening cardiac disease - participants with any of the following at Visit 1 would be excluded:

An MI or unstable angina in the last 8 weeks
Unstable or life-threatening cardiac arrhythmia requiring intervention in the last 8 weeks.

NOTE: Any participant who experiences unstable or life-threatening cardiac disease during the run-in period will be excluded but can be rescreened 8 weeks after the resolution of the event.

Pneumonia and/or moderate or severe COPD exacerbation that has not resolved at least 8 weeks prior to Visit 1
Any life-threatening condition, including malignancy, with a life expectancy < 5 years, other than CV disease or COPD, that might prevent the participant from completing the study.
Use of maintenance ICS treatment within the past 12 months.
Unable to abstain from protocol-defined prohibited medications
Participation in another clinical study with a study intervention administered in the last 30 days or 5 half-lives, whichever is longer prior to Visit 1 (any other investigational product that is not identified in protocol is prohibited for use during the duration of the study).
Participants with a known hypersensitivity to LAMA, LABA or ICS or any component of the MDI.
Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
Previous randomization in the present study.
For females only - currently pregnant (confirmed with positive pregnancy test) or breastfeeding

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение: Рандомизированное
Модель: Параллельные группы
Маскирование: Четверное слепое
Основная цель: Лечение